NCT01730638View on ClinicalTrials.gov

ImmunoTEP for Patients With Medullary Thyroid Carcinoma.

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Medullary Thyroid Carcinoma

Interventions

DRUG

• TF2 and 68 Ga-IMP-288

Trial Locations (3)

44100

Nantes Hospital, Nantes

44805

Institut de Cancérologie de l'ouest, René Gauducheau, Saint-Herblain

49100

Angers Hospital, Angers

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

collaborator

Gilead Sciences

INDUSTRY

lead

Nantes University Hospital

OTHER